KPKira PharmaceuticalsJTJasper Therapeutics, Inc.

Overview

Jasper Therapeutics agreed to acquire Kira Pharmaceuticals in an all-stock reverse merger, with a concurrent $132 million private placement. Kira's former equityholders receive about 49.9% of the combined company, the private placement investors about 43.5%, and Jasper's existing equityholders about 6.7%. Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront plus milestones.

Deal rationale

The combination creates a consolidated pipeline of immunology biologics, funded through the second half of 2028 by the private placement and out-licensing proceeds.

Timeline

1. AnnouncedJul 16, 2026Filing
2. ClosedJul 16, 2026

   Imported from prototype record 39, unverified

   Filing

Valuation and terms

Advisors

Parties